MRMichael B. Robinson

Michael B. Robinson

*This is an algorithmically generated author record based on publicly available information.

Michael B. Robinson has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Marco I. González

    Dept. of Pediatrics, Children’s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA 19104

    5 shared publications
  • Amanda L. Sheldon

    Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA 19104, USA

    4 shared publications
  • Bala T. S. Susarla

    Departments of Pediatrics and Pharmacology, Children’s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania, USA

    4 shared publications
  • Bala T.S. Susarla

    Dept. of Pediatrics, Children’s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA 19104

    2 shared publications
  • Deborah J. Watson

    Pathobiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA

    2 shared publications
  • John H. Wolfe

    Pathobiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA

    2 shared publications

Latest Publications

  • Ubiquitination-mediated internalization and degradation of the astroglial glutamate transporter, GLT-1

    by Amanda L. Sheldon, Marco I. González, Elizabeth N. Krizman-Genda, Bala T.S. Susarla, Michael B. Robinson


  • Open Access

    Caveolin-1 Regulates the Delivery and Endocytosis of the Glutamate Transporter, Excitatory Amino Acid Carrier 1

    by Marco I. González, Elizabeth Krizman-Genda, Michael B. Robinson


  • Open Access

    Constitutive endocytosis and recycling of the neuronal glutamate transporter, excitatory amino acid carrier 1

    by Marco I. González, Bala T. S. Susarla, Keith M. Fournier, Amanda L. Sheldon, Michael B. Robinson

    The neuronal glutamate transporter, excitatory amino acid carrier 1 (EAAC1), has a diverse array of physiologic and metabolic functions. There is evidence that there is a relatively large intracellular pool of EAAC1 both in vivo and in vitro, that EAAC1 cycles on and off the plasma membrane, and that EAAC1 cell surface expression can be rapidly regulated by intracellular signals. Despite the possible relevance of EAAC1 trafficking to both physiologic and pathologic processes, the cellular machinery involved has not been defined. In the present study, we found that agents that disrupt clathrin‐dependent endocytosis or plasma membrane cholesterol increased steady‐state levels of biotinylated EAAC1 in C6 glioma cells and primary neuronal cultures. Acute depletion of cholesterol increased the Vmax for EAAC1‐mediated activity and had no effect on Na+‐dependent glycine transport in the same system. These agents also impaired endocytosis as measured using a reversible biotinylating reagent. Co‐expression with dominant‐negative variants of dynamin or the clathrin adaptor, epidermal growth factor receptor pathway substrate clone 15, increased the steady‐state levels of biotinylated myc‐EAAC1. EAAC1 immunoreactivity was found in a subcellular fraction enriched in early endosome antigen 1 (EEA1) isolated by differential centrifugation and partially co‐localized with EEA1. Co‐expression of a dominant‐negative variant of Rab11 (Rab11 S25N) reduced steady‐state levels of biotinylated myc‐EAAC1 and slowed constitutive delivery of myc‐EAAC1 to the plasma membrane. Together, these observations suggest that EAAC1 is constitutively internalized via a clathrin‐ and dynamin‐dependent pathway into early endosomes and that EAAC1 is trafficked back to the cell surface via the endocytic recycling compartment in a Rab11‐dependent mechanism. As one defines the machinery required for constitutive trafficking of EAAC1, it may be possible to determine how intracellular signals regulate EAAC1 cell surface expression.


  • Regulation of astrocytic glutamate transporter expression by Akt: evidence for a selective transcriptional effect on the GLT‐1/EAAT2 subtype

    by Li‐Bin Li, Shuy Vang Toan, Olga Zelenaia, Deborah J. Watson, John H. Wolfe, Jeffrey D. Rothstein, Michael B. Robinson

    In the nervous system, astrocytes express different ratios of the two glial glutamate transporters, glutamate transporter subtype 1 (GLT‐1) and glutamate/aspartate transporter (GLAST), but little is known about the signaling pathways that independently regulate their expression. Treatment with dibutyryl‐cAMP, epidermal growth factor (EGF) or other growth factors both induces expression of GLT‐1 and increases expression of GLAST in astrocyte cultures. The induction of GLT‐1 is correlated with morphological and biochemical changes that are consistent with astrocyte maturation. Pharmacological studies suggest that phosphatidylinositol 3‐kinase (PI‐3K) and the nuclear transcription factor‐κB (NF‐κB) may be involved in the induction of GLT‐1 expression. In several signaling systems Akt, also known as protein kinase B (PKB), functions downstream of PI‐3K. In these present studies we used lentiviral vectors engineered to express dominant‐negative (DN), constitutively active (CA), or null variants of Akt to study the possible involvement of Akt in the regulation of GLT‐1. Expression of DN‐Akt attenuated the EGF‐dependent induction of GLT‐1. Expression of CA‐Akt caused a dose‐ and time‐dependent increase in GLT‐1 protein, increased GLT‐1 mRNA levels, increased dihydrokainate‐sensitive (presumably GLT‐1 mediated) transport activity, and caused a change in astrocyte morphology to a more stellate shape, but had no effect on GLAST protein levels. Finally, the expression of CA‐Akt increased the expression of a reporter construct containing a putative promoter fragment from the human homolog of GLT‐1, called EAAT2. From these studies, we conclude that Akt induces the expression of GLT‐1 through increased transcription and that Akt can regulate GLT‐1 expression without increasing GLAST expression in astrocytes.


  • Acute Regulation of Sodium-Dependent Glutamate Transporters: A Focus on Constitutive and Regulated Trafficking

    by M. B. Robinson

    The acidic amino acid glutamate activates a family of ligand-gated ion channels to mediate depolarization that can be as short-lived as a few milliseconds and activates a family of G protein-coupled receptors that couple to both ion channels and other second messenger pathways. Glutamate is the predominant excitatory neurotransmitter in the mammalian central nervous system and is required for essentially all motor, sensory, and cognitive functions. In addition, glutamate-mediated signaling is required for development and the synaptic plasticity thought to underlie memory formation and retrieval. The levels of glutamate in brain approach 10 mmol/kg and most cells in the CNS express at least one of the receptor subtypes. Unlike acetylcholine that mediates “rapid” excitatory neurotransmission at the neuromuscular junction, there is no evidence for extracellular inactivation of glutamate. Instead, glutamate is cleared by a family of Na+-dependent transport systems that are found on glial processes that sheath the synapse and found on the pre- and postsynaptic elements of neurons. These transporters ensure crisp excitatory transmission by maintaining synaptic concentrations below those required for tonic activation of glutamate receptors under baseline conditions (∼ µM) and serve to limit activation of glutamate receptors after release. During the past few years, it has become clear that like many of the other neurotransmitter transporters discussed in this volume of Handbook of Experimental Pharmacology, the activity of these transporters can be rapidly regulated by a variety of effectors. In this chapter, a broad overview of excitatory signaling will be followed by a brief introduction to the family of Na+-dependent glutamate transporters and a detailed discussion of our current understanding of the mechanisms that control transporter activity. The focus will be on our current understanding of the mechanisms that could regulate transporter activity within minutes, implying that this regulation is independent of transcriptional or translational control mechanisms. The glutamate transporters found in forebrain are regulated by redistributing the proteins to or from the plasma membrane; the signals involved and the net effects on transporter activity are being defined. In addition, there is evidence to suggest that the intrinsic activity of these transporters is also regulated by mechanisms that are independent of transporter redistribution; less is known about these events. As this field progresses, it should be possible to determine how this regulation affects physiologic and pathologic events in the CNS.


  • Open Access

    Evidence that protein kinase Cα interacts with and regulates the glial glutamate transporter GLT‐1

    by Marco I. González, Bala T. S. Susarla, Michael B. Robinson

    Many of the sodium‐dependent neurotransmitter transporters are rapidly (within minutes) regulated by protein kinase C (PKC), with changes in activity being correlated with changes in transporter trafficking to or from the plasma membrane. Our recent studies suggest that one of the classical subtypes of PKC, PKCα, may selectively mediate redistribution of the neuronal glutamate transporter, excitatory amino acid carrier (EAAC)1, and show that PKCα can be co‐immunoprecipitated with EAAC1. When the glial glutamate transporter GLT‐1a is transfected into C6 glioma cells, this transporter is internalized in response to activation of PKC, but the PKC subtype involved in this regulation is unknown. In the present study, expression of the phorbol ester‐activated subtypes of PKC was examined in C6 glioma transfected with GLT‐1. Of the classical subtypes, only PKCα was detected, and of the non‐classical subtypes, PKCδ and PKCε were detected. In this system, phorbol ester‐dependent internalization of GLT‐1 was blocked by a general inhibitor of PKCs (bisindolylmaleimide II) and by concentrations of Gö6976 that selectively block classical PKCs, but not by an inhibitor of PKCδ (rottlerin). PKCα immunoreactivity was found in GLT‐1 immunoprecipitates obtained from transfected C6 cells and from crude rat brain synaptosomes, a milieu that better mimicsin vivoconditions. The amount of PKCα in both types of immunoprecipitate was modestly increased by phorbol ester, and this increase was blocked by a PKC antagonist. These studies suggest that PKCα may be required for the regulated redistribution of GLT‐1.


  • Differential regulation of GLAST immunoreactivity and activity by protein kinase C: evidence for modification of amino and carboxyl termini

    by Bala T. S. Susarla, Rebecca P. Seal, Olga Zelenaia, Deborah J. Watson, John H. Wolfe, Susan G. Amara, Michael B. Robinson

    Many neurotransmitter transporters, including the GLT‐1 and EAAC1 subtypes of the glutamate transporter, are regulated by protein kinase C (PKC) and these effects are associated with changes in cell surface expression. In the present study, the effects of PKC activation on the glutamate aspartate transporter (GLAST) subtype of glutamate transporter were examined in primary astrocyte cultures. Acute (30 min) exposure to the phorbol 12‐myristate 13‐acetate (PMA) increased (approximately 20%) transport activity but had the opposite effect on both total and cell surface immunoreactivity. Chronic treatment (6 or 24 h) with PMA had no effect on transport activity but caused an even larger decrease in total and cell surface immunoreactivity. This loss of immunoreactivity was observed using antibodies directed against three different cytoplasmic epitopes, and was blocked by the PKC antagonist, bisindolylmaleimide II. We provide biochemical and pharmacological evidence that the activity observed after treatment with PMA is mediated by GLAST. Two different flag‐tagged variants of the human homolog of GLAST were introduced into astrocytes using lentiviral vectors. Although treatment with PMA caused a loss of transporter immunoreactivity, flag immunoreactivity did not change in amount or size. Together, these studies suggest that activation of PKC acutely up‐regulates GLAST activity, but also results in modification of several different intracellular epitopes so that they are no longer recognized by anti‐GLAST antibodies. We found that exposure of primary cultures of neurons/astrocytes to transient hypoxia/glucose deprivation also caused a loss of GLAST immunoreactivity that was attenuated by the PKC antagonist, bisindolylmaleimide II, suggesting that some acute insults previously thought to cause a loss of GLAST protein may mimic the phenomenon observed in the present study.